Trial Profile

Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir (Primary)
Indications Hepatitis C
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

27 Aug 2021 Status changed from recruiting to discontinued.
02 May 2018 Status changed from not yet recruiting to recruiting.
24 Apr 2018 Planned End Date changed from 31 Aug 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com